Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis-Reference-Cited by-同舟云学术

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

Published:2019-12 Issue:12 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Berliba Elina¹,Bogus Maxim¹,Vanhoutte Frédéric²,Berghmans Pieter-Jan²,Good Steven S.³,Moussa Adel³,Pietropaolo Keith³,Murphy Robert L.³⁴,Zhou Xiao-Jian³,Sommadossi Jean-Pierre³

Affiliation:

1. ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chisinau, Moldova

2. SGS Life Sciences, Antwerp, Belgium

3. Atea Pharmaceuticals, Inc., Boston, Massachusetts, USA

4. Northwestern University, Chicago, Illinois, USA

Abstract

AT-527 is a novel modified guanosine nucleotide prodrug inhibitor of the hepatitis C virus (HCV) NS5B polymerase, with increased in vitro antiviral activity compared to sofosbuvir and a highly differentiated favorable preclinical profile compared to other anti-HCV nucleoside/nucleotide analogs.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01201-19

Reference27 articles.

1. World Health Organization. 2017. Global hepatitis report, 2017. World Health Organization, Geneva, Switzerland. https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=8EB397C58B3837AB5F66A2E8C53A8718?sequence=1. Accessed 23 September 2019.

2. AASLD-IDSA. 2019. Recommendations for testing managing and treating hepatitis C. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. http://www.hcvguidelines.org. Accessed 23 September 2019.

3. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection

4. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3

5. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proximal fleximer analogues of 2′-deoxy-2′-fluoro-2′-methyl purine nucleos(t)ides: Synthesis and preliminary pharmacokinetic and antiviral evaluation;Bioorganic & Medicinal Chemistry;2024-10

2. Synthesis of Fluorinated Nucleosides/Nucleotides and Their Antiviral Properties;Molecules;2024-05-19

3. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19;Journal of Antimicrobial Chemotherapy;2024-05-06

4. Shaping the future of antiviral Treatment: Spotlight on Nucleobase-Containing drugs and their revolutionary impact;Bioorganic Chemistry;2024-03

5. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19;2024-01-08